EVHNYSEServices-Management ServicesFiscal year ends December 31
Evolent Health, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.48−0.09 (-1.97%)
Close on Oct 19, 2026
- Market cap
- $504.19M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.05 (−40.50%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Evolent Health, Inc. saw revenue fall 4.5% to $2.10B over the twelve months to Jun 30, 2026.
Revenue
$2.10B
-4.5% vs. a year earlier
Operating income
-$427.51M
TTM Q2 2026
EPS, diluted
-$4.57
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $504.19M
- P/E ratio
- –
- Price to sales
- 0.24
- Price to book
- 1.32
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.10B
- Net income
- -$504.99M
- EPS, diluted
- -$4.57
- Book value per share
- $3.41
- Diluted shares
- 113M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$2.10B-4.5% YoY
Gross profit
$361.64M+0.7% YoY
Operating income
-$427.51M
Net income
-$504.99M
EPS, diluted
-$4.57
Free cash flow
–
Reported periodTrailing twelve months